Compared to many other histomorphological or molecular features of CRCs, which have been established to guide therapeutic decisions, such as tumor budding [21], tumor deposits [22], consensus molecular subtypes [23], microsatellite status [24], and EGFR- or BRAF-mutation status, SARIFA does not need any further expensive testing and provides an extremely low interobserver variability [16,17]; thus, it is easy to implement into the diagnostic workflow. The gene discussed is EGFR; the disease is neoplasm.